Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
48
ATXS Quote, Financials, Valuation and Earnings
Last price:
$13.12
Seasonality move
:
28.87%
Day range:
$13.06 - $13.29
52-week range:
$3.56 - $13.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1,068.20x
P/B ratio:
5.42x
Volume:
5.7M
Avg. volume:
1.2M
1-year change:
29.39%
Market cap:
$747.2M
Revenue:
--
EPS (TTM):
-$2.15
Analysts' Opinion
-
Consensus RatingAstria Therapeutics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $24.60, Astria Therapeutics, Inc. has an estimated upside of 87.93% from its current price of $13.12.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $13.00 representing 100% downside risk from its current price of $13.12.
Fair Value
-
According to the consensus of 8 analysts, Astria Therapeutics, Inc. has 87.93% upside to fair value with a price target of $24.60 per share.
ATXS vs. S&P 500
-
Over the past 5 trading days, Astria Therapeutics, Inc. has overperformed the S&P 500 by 6.07% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Astria Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Astria Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Astria Therapeutics, Inc. reported revenues of $706K.
Earnings Growth
-
Astria Therapeutics, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Astria Therapeutics, Inc. reported earnings per share of -$0.55.
Enterprise value:
619.3M
EV / Invested capital:
2.61x
Price / LTM sales:
1,068.20x
EV / EBIT:
--
EV / Revenue:
877.20x
PEG ratio (5yr expected):
-2.23x
EV / Free cash flow:
-5.15x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-39.55%
Net Income Margin (TTM):
-17567.99%
Return On Equity:
-42.95%
Return On Invested Capital:
-42.21%
Operating Margin:
-4830.6%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $706K | -- | $706K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$63.1M | -$101M | -$136.5M | -$29M | -$34.1M | |
| EBITDA | -$63.1M | -$101M | -$136.5M | -$29M | -$34.1M | |
| Diluted EPS | -$2.20 | -$2.09 | -$2.15 | -$0.42 | -$0.55 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $134.5M | $118.5M | $191.5M | $351.9M | $253.5M | |
| Total Assets | $135.1M | $119.8M | $193.9M | $361.6M | $271.9M | |
| Current Liabilities | $4.7M | $6.4M | $9.4M | $15.7M | $23.5M | |
| Total Liabilities | $4.7M | $6.9M | $9.4M | $20M | $38.6M | |
| Total Equity | $130.4M | $112.9M | $184.5M | $341.7M | $233.3M | |
| Total Debt | $541K | $504K | -- | $4.3M | $3.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$48.9M | -$94.1M | -$119.7M | -$28M | -$32.3M | |
| Cash From Investing | $1.9M | -$190.2M | $135.1M | $6.2M | $52.3M | |
| Cash From Financing | $120.8M | $245.2M | $3K | $15.3M | $3K | |
| Free Cash Flow | -$48.9M | -$94.4M | -$120.3M | -$28M | -$32.3M | |
ATXS
Sector
Market Cap
$747.2M
$28.4M
Price % of 52-Week High
99.92%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
0.06%
-1.32%
1-Year Price Total Return
27.96%
-22.19%
Beta (5-Year)
0.076
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$12.67
200-day SMA
Buy
Level
$7.22
Bollinger Bands (100)
Buy
Level
6.37 - 11.69
Chaikin Money Flow
Sell
Level
-409.4M
20-day SMA
Buy
Level
$12.57
Relative Strength Index (RSI14)
Buy
Level
74.17
ADX Line
Buy
Level
32.66
Williams %R
Sell
Level
-1.227
50-day SMA
Buy
Level
$11.22
MACD (12, 26)
Buy
Level
0.39
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
672.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (12.8516)
Buy
CA Score
(Annual)
Level (-0.1215)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (5.2748)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, ATXS has received 1 Buy ratings 7 Hold ratings, and 0 Sell ratings. The ATXS average analyst price target in the past 3 months is $24.60.
-
Where Will Astria Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Astria Therapeutics, Inc. share price will rise to $24.60 per share over the next 12 months.
-
What Do Analysts Say About Astria Therapeutics, Inc.?
Analysts are divided on their view about Astria Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Astria Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $13.00.
-
What Is Astria Therapeutics, Inc.'s Price Target?
The price target for Astria Therapeutics, Inc. over the next 1-year time period is forecast to be $24.60 according to 8 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is ATXS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Astria Therapeutics, Inc. is a Hold. 7 of 8 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of ATXS?
You can purchase shares of Astria Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Astria Therapeutics, Inc. shares.
-
What Is The Astria Therapeutics, Inc. Share Price Today?
Astria Therapeutics, Inc. was last trading at $13.12 per share. This represents the most recent stock quote for Astria Therapeutics, Inc.. Yesterday, Astria Therapeutics, Inc. closed at $13.12 per share.
-
How To Buy Astria Therapeutics, Inc. Stock Online?
In order to purchase Astria Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ATXS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ATXS
Sector
P/E ratio
--
23.66x
PEG ratio
-2.23x
-0.01x
P/B ratio
5.42x
1.84x
Price / LTM sales
1,068.20x
1.60x
Growth Metrics
ATXS
Sector
Revenue growth
--
4.85%
Earnings growth
-28.57%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.42
-$0.20
Profitability
ATXS
Sector
Profitability FY 2024
--
$3.6M
Return on invested capital
-42.21%
-30.98%
Return on assets
-39.55%
-27.62%
Return on equity
-42.95%
-36.69%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
18
Estimated Next Earnings Date
Feb
11
Balance Sheet
ATXS
Sector
Total cash
$227.7M
$27.2M
Short term investments
$268.3M
$25.7M
Total assets
$342.4M
$79.9M
Long term debt
$3.1M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
64
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
